5 stories mentioning COGTUpdated 13d ago
Every FINWIRES story that references COGT, newest first.
Arlene Morris, Director, on August 27, 2026, sold 45,510 shares in Cogent Biosciences (COGT) for $1,689,493.SEC Filing:https://www.sec.gov/Archives/edgar/data/1622229/000119312526377001/xslF345X05/ownership.xml
Healthcare stocks edged lower Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing about 0.1%.The iShares Biotechnology ETF (IBB) rose 0.5%.In corporate news, Jazz Pharmaceuticals (JAZZ) shares fell 1.3% after it said a phase 3 trial of Zepzelca in second-line metastatic small cell lung cancer failed to meet its primary endpoint.Avalo Therapeutics' (AVTX) lead drug abdakibart is now a cleaner immunology story following positive phase 2 trial data to treat skin disease hidradenitis suppurativa, BofA Securities said. BofA started coverage of the stock with a buy rating and a price target of $35. Avalo shares jumped 6%.Cogent Biosciences (COGT) said Bezuclastinib showed "rapid and deep" clinical benefit in advanced systemic mastocytosis patientsfollowing detailed and updated trial results. Shares rose 1.6%.
Healthcare stocks rose Thursday afternoon, with the NYSE Healthcare Index rising 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.2%.The iShares Biotechnology ETF (IBB) increased 1.1%.In corporate news, Eli Lilly's (LLY) weight-loss drugs secured coverage from the three largest US pharmacy benefit managers, the drugmaker said Thursday. Lilly shares gained 3.6%.Agilent Technologies (A) stock jumped 19% after the company posted higher fiscal Q2 adjusted earnings and revenue, and raised its fiscal 2026 adjusted EPS guidance.Illumina (ILMN) shares climbed 4.9% after it said it launched a whole-genome sequencing research workflow for molecular residual disease detection.Cogent Biosciences (COGT) shares added 2.4% after it said the US Food and Drug Administration has accepted its new drug application for bezuclastinib plus sunitinib to treat patients with gastrointestinal stromal tumors who have been treated with imatinib previously.
Healthcare stocks rose Thursday afternoon, with the NYSE Healthcare Index rising 1.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.3%.The iShares Biotechnology ETF (IBB) increased 1.1%.In corporate news, Cogent Biosciences (COGT) shares climbed 3.2% after it said Thursday the US Food and Drug Administration has accepted its new drug application for bezuclastinib plus sunitinib to treat patients with gastrointestinal stromal tumors who have been treated with imatinib previously.
Cogent Biosciences (COGT) said Thursday the US Food and Drug Administration has accepted its new drug application for bezuclastinib in combination with sunitinib to treat patients with gastrointestinal stromal tumors who have been treated with imatinib previously.The FDA has granted the application a priority review and assigned a Prescription Drug User Fee Act target action date of Nov. 30, the company said.The drug regulator has also said there is no plan to hold an advisory committee at this time, Cogent added.Price: $34.88, Change: $+0.37, Percent Change: +1.07%
